The Induction Mechanism of Ferroptosis, Necroptosis, and Pyroptosis in Inflammatory Bowel Disease, Colorectal Cancer, and Intestinal Injury

被引:14
|
作者
Zhou, Ping [1 ,2 ]
Zhang, Shun [1 ,2 ]
Wang, Maohua [1 ,2 ]
Zhou, Jun [1 ,2 ]
机构
[1] Southwest Med Univ, Dept Anesthesiol, Affiliated Hosp, Luzhou 646000, Peoples R China
[2] Anesthesiol & Crit Care Med Key Lab Luzhou, Luzhou 646000, Peoples R China
基金
中国国家自然科学基金;
关键词
ferroptosis; necroptosis; pyroptosis; inflammatory bowel disease; colorectal cancer; intestinal injury; CELL-DEATH; EXPERIMENTAL COLITIS; LIPID-PEROXIDATION; GASDERMIN D; ACTIVATION; PATHWAY; INHIBITION; TRIGGERS; NLRP3; CHEMOSENSITIVITY;
D O I
10.3390/biom13050820
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cell death includes programmed and nonprogrammed cell death. The former mainly includes ferroptosis, necroptosis, pyroptosis, autophagy, and apoptosis, while the latter refers to necrosis. Accumulating evidence shows that ferroptosis, necroptosis, and pyroptosis play essential regulatory roles in the development of intestinal diseases. In recent years, the incidence of inflammatory bowel disease (IBD), colorectal cancer (CRC), and intestinal injury induced by intestinal ischemia-reperfusion (I/R), sepsis, and radiation have gradually increased, posing a significant threat to human health. The advancement in targeted therapies for intestinal diseases based on ferroptosis, necroptosis, and pyroptosis provides new strategies for treating intestinal diseases. Herein, we review ferroptosis, necroptosis, and pyroptosis with respect to intestinal disease regulation and highlight the underlying molecular mechanisms for potential therapeutic applications.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Nutrigenomic underpinnings of intestinal stem cells in inflammatory bowel disease and colorectal cancer development
    Ho, Jennifer
    Puoplo, Nicholas
    Pokharel, Namrata
    Hirdaramani, Aanya
    Hanyaloglu, Aylin C.
    Cheng, Chia-Wei
    FRONTIERS IN GENETICS, 2024, 15
  • [22] Chemoprevention of colorectal cancer in inflammatory bowel disease
    Subramanian, Venkataraman
    Logan, Richard F.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2011, 25 (4-5) : 593 - 606
  • [23] Interval Colorectal Cancer in Inflammatory Bowel Disease
    Da Cunha, Teresa
    Vaziri, Haleh
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2024, 58 (01) : 1 - 11
  • [24] Colorectal cancer in idiopathic inflammatory bowel disease
    Harpaz, N
    Talbot, IC
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 1996, 13 (04) : 339 - 357
  • [25] Colorectal cancer and dysplasia in inflammatory bowel disease
    Timothy L Zisman
    David T Rubin
    World Journal of Gastroenterology, 2008, (17) : 2662 - 2669
  • [26] Chemoprevention of colorectal cancer in inflammatory bowel disease
    Ehrlich, Adam C.
    Patel, Shyam
    Meillier, Andrew
    Rothstein, Robin D.
    Friedenberg, Frank K.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (03) : 247 - 255
  • [27] Chemoprevention of colorectal cancer in inflammatory bowel disease
    Munkholm, P
    IBD AND SALICYLATES - 5, 2001, 24 (01): : 51 - 57
  • [28] Chemoprevention of colorectal cancer in inflammatory bowel disease
    Butterworth, J. R.
    DIGESTIVE AND LIVER DISEASE, 2009, 41 (05) : 338 - 339
  • [29] Colorectal cancer and dysplasia in inflammatory bowel disease
    Zisman, Timothy L.
    Rubin, David T.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (17) : 2662 - 2669
  • [30] Incidence of colorectal cancer in inflammatory bowel disease
    Liu, Liyan
    Velayos, Fernando
    Allison, James
    Terdiman, Jonathan
    Lewis, James
    Hutfless, Susan
    Herrinton, Lisa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S442 - S442